Updates are available Correction dated 2024-08-28
Click to view Correction: https://doi.org/10.1007/s40121-024-01033-x
-
Authors
Shields, Ryan K. https://orcid.org/0000-0001-9794-5665
Horcajada, Juan P. https://orcid.org/0000-0001-9873-5459
Kamat, Shweta https://orcid.org/0000-0003-3584-5014
Irani, Paurus M.
Tawadrous, Margaret https://orcid.org/0000-0002-6815-2647
Welte, Tobias https://orcid.org/0000-0002-9947-7356
-
Funding
Funding for this research was provided by:
Pfizer Foundation
- License Information
-
More Information
Article History
Received: 15 November 2023
Accepted: 17 May 2024
First Online: 31 May 2024
Change Date: 28 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40121-024-01033-x
Declarations
:
: Shweta Kamat and Paurus M. Irani are current employees of Pfizer and may hold stock/stock options with Pfizer. Margaret Tawadrous was an employee of Pfizer when this analysis was conducted. Ryan K. Shields is an employee of University of Pittsburgh and has served as a consultant for Allergan, Cidara, Entasis, GlaxoSmithKline, Melinta, Menarini, Merck, Pfizer, Shionogi, Utility, and Venatorx, and has received investigator-initiated funding from Merck, Melinta, Roche, Shionogi, and Venatorx; Juan P. Horcajada is an employee of Hospital del Mar and University of Pompeu Fabra, Barcelona, Spain and has received honoraria for advisory activities and served as a speaker for Pharma companies; Tobias Welte is an employee of Hannover School of Medicine and has received fees for lectures and served in advisory board for AstraZeneca and Pfizer.
: This article is based on published literature and does not contain any previously unreported studies with human participants or animals.
